James O’Brien's most recent trade in Albemarle Corp. was a trade of 2,725 Common Stock done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Albemarle | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 2,725 | 8,048 (0%) | 0% | 0 | Common Stock | |
| Albemarle | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 37 | 8,085 (0%) | 0% | 0 | Common Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 1,575 | 5,378 (0%) | 0% | 0 | Common Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2025 | 412 | 16,525 | - | - | Phantom Stock Units | |
| LQR House Inc | James O’Brien | Director | 31 Mar 2025 | 156 | 314 | - | - | Restricted Stock Units | ||
| LQR House Inc | James O’Brien | Director | 31 Mar 2025 | 156 | 936 | - | 0 | Common Stock | ||
| LQR House Inc | James O’Brien | Director | 03 Jan 2025 | 780 | 780 | - | 0 | Common Stock | ||
| LQR House Inc | James O’Brien | Director | 03 Jan 2025 | 780 | 470 | - | - | Restricted Stock Units | ||
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2024 | 277 | 15,640 | - | - | Phantom Stock Units | |
| Albemarle | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,750 | 5,313 (0%) | 0% | 0 | Common Stock | |
| Albemarle | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 10 | 5,323 (0%) | 0% | 0 | Common Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 1,252 | 3,803 (0%) | 0% | 0 | Common Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 303 | 15,131 | - | - | Phantom Stock Units | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2023 | 408 | 14,547 | - | - | Phantom Stock Units | |
| Albemarle | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 750 | 3,563 (0%) | 0% | 0 | Common Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 1,396 | 2,551 (0%) | 0% | 0 | Common Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 369 | 13,855 | - | - | Phantom Stock Units | |
| Humana | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 380 | 1,794 (0%) | 0% | 0 | Humana Common | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2022 | 417 | 13,299 | - | - | Phantom Stock Units | |
| Albemarle | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 731 | 2,813 (0%) | 0% | 0 | Common Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 1,041 | 12,523 | - | - | Phantom Stock Units | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 270 | 11,467 | - | - | Phantom Stock Units | |
| Cognition Therapeutics Inc | James M. O’Brien | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Humana | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 412 | 1,414 (0%) | 0% | 0 | Humana Common | |
| Cognition Therapeutics Inc | James M. O’Brien | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 12.00 per share. | 13 Oct 2021 | 5,000 | 5,000 | - | 12 | 60,000 | Common Stock |
| Cognition Therapeutics Inc | James M. O’Brien | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 54,457 | 54,457 | - | - | Stock Option (right to buy) | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 294 | 11,084 | - | - | Phantom Stock Units | |
| Albemarle | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 775 | 15,003 | - | - | Phantom Stock | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2021 | 807 | 10,591 | - | - | Phantom Stock Units | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2021 | 270 | 9,801 | - | - | Phantom Stock Units | |
| Humana | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 403 | 1,002 (0%) | 0% | 0 | Humana Common | |
| Eastman Chemical | James J. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2020 | 384 | 9,296 | - | - | Phantom Stock Units |